Related Experiment Video

Updated: Feb 19, 2026

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

3.0K

Hsp-27 levels and thrombus burden relate to clinical outcomes in patients with ST-segment elevation myocardial

Maozhou Tian1, Lingmin Zhu2, Hongyang Lin3

  • 1Department of Cardiac Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shangdong 264000, P.R. China.

Oncotarget
|November 2, 2017
PubMed

Insights

High levels of Heat Shock Protein-27 (Hsp-27) in ST-segment elevation myocardial infarction (STEMI) patients correlate with increased thrombus burden and major adverse cardiovascular events (MACE). This finding may aid in predicting outcomes post-primary percutaneous coronary intervention (pPCI).

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Interventional Cardiology

Background:

  • High thrombus burden in ST-segment elevation myocardial infarction (STEMI) complicates urgent revascularization, leading to poor outcomes.
  • The role of Heat Shock Protein-27 (Hsp-27) in relation to thrombus burden and clinical outcomes in STEMI patients remains unclear.
  • Understanding novel biomarkers is crucial for improving risk stratification in STEMI.

Purpose of the Study:

  • To investigate the association between plasma Hsp-27 levels and thrombus burden in STEMI patients undergoing primary percutaneous coronary intervention (pPCI).
  • To evaluate the predictive value of Hsp-27 for major adverse cardiovascular events (MACE) in this patient cohort.

Main Methods:

  • Prospective study of 146 STEMI patients undergoing pPCI within 12 hours of symptom onset.
  • Patients were categorized into low and high thrombus burden groups.
  • Plasma Hsp-27 levels were measured; association with thrombus burden and MACE was analyzed using ROC curves and multivariate Cox regression.

Main Results:

  • Patients with high thrombus burden exhibited significantly higher plasma Hsp-27 levels (58.0 ± 12.3 ng/mL) compared to those with low thrombus burden (32.0 ± 8.6 ng/mL).
  • Plasma Hsp-27 levels demonstrated significant diagnostic value for high thrombus burden (AUC, 0.847).
  • Hsp-27 levels > 45 ng/mL were positively correlated with a higher incidence of MACE (HR 2.801) and lower MACE-free survival at 180 days.

Conclusions:

  • Plasma Hsp-27 is positively correlated with high thrombus burden in STEMI patients undergoing pPCI.
  • Elevated plasma Hsp-27 levels serve as a significant predictor of MACE in STEMI patients.
  • Hsp-27 may be a valuable biomarker for risk stratification and outcome prediction in STEMI.

Keywords:
Hsp-27STEMImajor adverse cardiovascular eventthrombus burden

More Related Videos

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

10.2K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
309
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
365
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
392
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
947
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
552